Principal investigator responsibilities under ICH GCP: a practical guide for 2026
The principal investigator is the single most accountable person at any clinical trial site. The success of a trial hinges on the PI’s ability to protect participants, maintain clean data, and adhere to the protocol. When a trial goes wrong, the PI is the first person a regulatory inspector will look to.
Understanding the responsibilities of a principal investigator under GCP is not optional for anyone working in or around clinical research. It is the foundation of every compliant, ethical, and scientifically valid study. And those duties have changed since 2026. The finalisation of ICH GCP E6 R3 introduces a new set of expectations for investigators, including a fundamental shift toward proactive quality management, proportionate oversight, and personal accountability for trial integrity. For a full breakdown of the framework, see our guide to the ICH E6 R3 principles. This guide covers everything: what the role requires, what changed under R3, how delegation works, and what happens when things go wrong.
A principal investigator (PI) is the individual responsible for the conduct of a clinical trial at a site. Under ICH GCP, principal investigator responsibilities GCP include ensuring participant safety, overseeing all delegated trial activities, maintaining essential documents, ensuring valid informed consent, and supervising all site staff. ICH E6 R3 strengthens these obligations with new emphasis on quality oversight, proportionate risk management, and active involvement in trial design feasibility.
What is a principal investigator in clinical research?
A principal investigator in clinical research is the person who takes overall responsibility for the conduct of a clinical trial at a given site. The PI is the human face of GCP compliance at site level, the individual who signs the protocol agreement, oversees the team, ensures participants are protected, and stands accountable to both the sponsor and the regulatory authority.
In practical terms, the PI is typically a licensed healthcare professional, most commonly a physician or, where permitted by local regulation, a dentist or other qualified healthcare professional. What matters under ICH GCP is not the specific professional title but the combination of education, training, and experience that qualifies the individual to take on this level of clinical and regulatory responsibility.
A PI may run a single-site trial or serve as the coordinating investigator across multiple sites. In some studies, particularly investigator-initiated trials, the same individual acts as both sponsor and investigator, carrying a dual set of obligations that must be carefully documented and managed.
What is the difference between a principal investigator and a sub-investigator?
The distinction is one of accountability, not simply seniority.
The PI holds overall site responsibility and cannot transfer that accountability to anyone else.
A sub-investigator is any member of the clinical trial team at the site who has been delegated specific trial-related tasks by the PI, documented on the delegation of authority log.
Sub-investigators may include co-investigators, resident physicians, study nurses, or specialist clinicians brought in to perform specific assessments. They work under the PI’s supervision and within the scope defined on the delegation log. They do not carry independent GCP accountability; their accountability flows through the PI. If a sub-investigator makes a documentation error, misses a protocol step, or fails to obtain re-consent after an amendment, the PI is ultimately responsible for that failure having occurred on their watch.
This is one of the most important and most misunderstood aspects of principal investigator responsibilities under GCP: the PI can delegate a task, but cannot delegate the obligation to ensure that task is performed correctly.
Principal investigator responsibilities under ICH GCP: the full picture
ICH E6 R3 structures investigator responsibilities across several interconnected areas. Each is examined in detail below.
Participant safety and medical care
The most fundamental of all principal investigator responsibilities under GCP is the protection of trial participants. Under both R2 and R3, a qualified physician must always have overall responsibility for the trial-related medical care of participants. This responsibility cannot be delegated. Even when a nurse or coordinator conducts day-to-day participant interactions, a physician must be available and engaged whenever a medical decision is required.
ICH E6 R3 reinforces this by emphasising that the PI must ensure medical decisions, including decisions about whether to continue, modify, or discontinue a participant’s involvement based on safety findings, are made promptly and are appropriately documented. The guideline also makes clear that the PI must ensure any adverse events are assessed for seriousness, causality, and expectedness in a clinically appropriate and timely manner.
Under R3, there is also increased emphasis on the PI’s responsibility to ensure the trial design itself does not create unnecessary medical risk. This connects the principal investigator’s responsibilities under GCP directly to the study feasibility assessment; a PI who agrees to conduct a trial that is beyond the site’s capability is already failing in their obligations before the first participant is enrolled.
Protocol compliance and feasibility
The PI must ensure that the trial is conducted strictly in accordance with the approved protocol, the ICH GCP guidelines, and all applicable regulatory requirements. This sounds straightforward. In practice, it requires the PI to have a detailed, working knowledge of the protocol, not a general familiarity, but genuine expertise in the study design, inclusion and exclusion criteria, study procedures, and stopping rules.
ICH E6 R3 introduces an important new dimension to this responsibility. Proportionality, one of the genuinely new principles introduced in R3, means that the PI must now actively assess whether the demands of the protocol are proportionate to the risks participants face and the importance of the data being collected. A PI who conducts a low-risk, low-intervention study with the same administrative intensity as a first-in-human trial is no longer acting in alignment with current GCP expectations.
Before the trial begins, the PI is expected to review the protocol for feasibility, assessing whether the site has the required resources, facilities, qualified staff, and patient population to conduct the study correctly. If the PI has concerns about any of these elements, R3 is explicit that these concerns must be communicated to the sponsor before the trial starts. Signing the protocol agreement without raising known concerns is a compliance failure in itself.
Informed consent oversight
The PI holds overall responsibility for the informed consent process at the site. While the PI may delegate the consent discussion to a qualified sub-investigator or CRC, they must ensure that whoever conducts the discussion is appropriately trained, knowledgeable about the trial, and capable of answering participant questions accurately.
Under ICH E6 R3, the principal investigator’s responsibilities in relation to informed consent go further than simply ensuring a form is signed. The PI must satisfy themselves that the consent process is genuinely participant-centred, that participants receive information in a form they can understand, that they are given sufficient time to consider, and that their ongoing consent is actively maintained throughout the trial. When a protocol amendment or new safety data requires re-consent, the PI is accountable for ensuring this happens before the affected participants continue in the study.
Informed consent is one of the most scrutinised areas of PI responsibility during inspections. The most common findings include consent obtained after study procedures had already started, outdated consent form versions used, insufficient documentation of the consent discussion, and failure to re-consent following a protocol amendment.
Each of these findings traces directly back to the principal investigator’s responsibilities under GCP. The PI is accountable for the consent process at the site, regardless of who conducted the discussion. For a detailed breakdown of the consent process and documentation requirements, see our complete guide to informed consent in clinical trials.
Delegation of responsibilities and the delegation log
One of the most practically important aspects of principal investigator responsibilities is the management of the delegation log. The delegation of authority log is the document that records which trial-related tasks have been assigned to which team members, along with their qualifications and the dates during which each delegation was active.
Under ICH GCP, every person performing a trial-related task at the site must appear on the delegation log before they perform that task. The PI must sign the log, confirming that each delegated individual is appropriately qualified for the tasks assigned to them. The log must be kept current. When team members join or leave the study, or when their responsibilities change, the log must be updated promptly.
ICH E6 R3 strengthens the language around delegation oversight considerably. R3 makes explicit that the PI must not simply sign the delegation log and move on. The PI is expected to supervise delegated activities actively, which means regular engagement with the team, review of data and documentation, and prompt identification and correction of any deviations from the protocol or GCP.
The following rules apply to delegation under the current ICH GCP:
The PI may delegate a task to any qualified team member but must document this delegation formally. The delegated individual must have the training, qualifications, and experience to perform the task. The PI must ensure the delegated task is performed correctly and in accordance with the protocol. The PI retains full accountability for all delegated activities. No delegation of any kind is valid unless it appears on the current signed delegation log.
Essential documents and record keeping
The principal investigator is responsible for maintaining and retaining all site-level essential documents throughout the trial and for the required retention period afterwards. Essential documents are the records that, taken together, allow the reconstruction and evaluation of the trial conduct and data quality. They include the signed protocol and amendments, the current approved investigator brochure, all versions of the informed consent form, the delegation log, training records, laboratory certifications, regulatory approvals, correspondence with the sponsor, and all participant data records.
Under R3, the PI’s responsibility for essential documents extends to ensuring that records are maintained in accordance with the ALCOA++ principles, that they are attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available, and traceable. This applies regardless of whether records are held on paper or in an electronic system. Where electronic systems are used, the principal investigator must ensure these systems are validated and that audit trails are activated and maintained.
For a full guide to documentation standards, see our post on good documentation practice and data integrity.
ICH GCP E6 R3 updates: what changed for investigators?
This is the section that matters most for professionals who trained under R2 and need to understand where principal investigator responsibilities GCP have specifically evolved.
For a full comparison of R2 and R3 across all areas of GCP, see our detailed guide to what changed in R3.
From compliance to quality ownership
The most significant philosophical shift in R3 for investigators is the move from reactive compliance to proactive quality ownership. Under R2, the expectation was essentially that the PI would follow the protocol and report problems when they arose. Under R3, the expectation is that the PI participates in building quality into the trial from the start.
This means the PI is now expected to contribute to the identification of Critical to Quality (CtQ) factors, the elements of the trial that are most important to participant safety and the reliability of results. A principal investigator who simply receives a protocol from a sponsor and begins enrolling without engaging in this quality planning process is operating below the standard R3 sets.
Proportionate oversight
R3’s principle of proportionality has direct implications for how PIs structure their oversight activities. Not every trial carries the same risk. A principal investigator overseeing a low-intervention observational study does not need to apply the same monitoring intensity, documentation burden, or oversight frequency as a PI running a first-in-human oncology trial.
R3 explicitly asks investigators to apply a proportionate approach, to focus their attention and resources on the aspects of the trial that carry the most risk to participants or the most importance for data quality. This is a significant change from the R2 culture of uniform process compliance.
Broader qualification requirements
R3 widens the definition of what makes an investigator qualified. Under R2, qualifications were assessed primarily through education and training credentials. R3 adds a stronger emphasis on ongoing competency, the idea that the principal investigator must remain current not just with the protocol but with evolving GCP standards, new technology used in the trial, and any emerging safety signals relevant to the study population.
This means that principal investigator responsibilities now include a responsibility for continuous professional development in GCP. A PI certified only under R2 who has not updated their training is, under the spirit of R3, operating with an incomplete understanding of their current obligations.
Oversight of decentralised and remote elements
ICH E6 R3 is the first version of the GCP guideline to explicitly address decentralised clinical trials (DCTs). For PIs, this introduces new oversight responsibilities. When trial activities take place remotely, including eConsent, remote patient assessments, wearable data collection, or home visits by nurses, the PI retains accountability for the quality and GCP compliance of those activities, even when they take place entirely outside the physical trial site.
This is a genuinely new area of principal investigator responsibilities that did not exist in R2. The principal investigators must now understand how remote trial processes are documented, how participant safety is monitored in a decentralised setting, and how oversight is maintained when they cannot directly observe the conduct of certain study procedures.
Principal investigator vs sub-investigator: a practical comparison
| Responsibility | Principal investigator | Sub-investigator |
|---|---|---|
| Overall site accountability | Yes, cannot be delegated | No |
| Medical decisions for participants | Yes, must be a qualified physician | Only if delegated and qualified |
| Signing delegation log | Yes, PI signs | Appears on log as delegate |
| Conducting informed consent | Yes, but may delegate | Yes, if delegated |
| Protocol compliance | Accountable for entire site | Accountable for delegated tasks |
| Essential document retention | Primary responsibility | Supporting role |
| Adverse event assessment | PI accountable | May contribute if delegated |
| Communication with sponsor/CRO | Primary contact | As directed by PI |
Are you a physician ready to lead your own research site? Knowing your responsibilities is the first step—building the infrastructure to support them is the next. If you are a medical doctor looking to transition into research, our specialized course “Setting up a successful clinical trial site: the principal investigator’s roadmap” provides the exact blueprint you need to stay compliant and profitable.
What happens if a principal investigator is non-compliant?
Regulatory consequences
Non-compliance with principal investigator responsibilities can have serious and wide-ranging consequences. At the inspection level, findings against a PI may range from observations (minor) to critical findings that place an immediate clinical hold on the study. Repeated or serious findings can result in the disqualification of the investigator, a formal regulatory action that prevents the individual from conducting trials for a defined period or permanently.
In the United States, the FDA maintains a list of disqualified and restricted investigators under 21 CFR Part 312. In Europe, EMA inspection findings against investigators are shared across member states. A disqualified investigator in one jurisdiction is typically scrutinised more closely, and sometimes rejected outright, by regulatory authorities in others.
Learn how to prepare for a GCP audit by reviewing our GCP audit preparation guide to prevent non-compliance issues.
Impact on trial data
When a PI is found to have committed serious GCP violations, the regulatory authority may invalidate some or all of the data generated at that site. In a multi-site trial, this may be manageable if the affected site contributed a small proportion of the overall dataset. In a single-site study, invalidated data can mean the entire development programme for a new medicine is halted.
This is why principal investigator responsibilities GCP are not simply a personal compliance matter, they have direct consequences for the patients waiting for the treatments being studied.
Sponsor obligations when a PI is non-compliant
When a sponsor or CRO becomes aware that a PI is not fulfilling their obligations, they have their own GCP obligations to act. Under R3, this includes escalating the issue through the trial’s quality management system, implementing corrective and preventive actions (CAPAs), increasing oversight at the affected site, and if necessary, suspending enrolment or terminating the site. The sponsor cannot simply note the problem and continue, inaction in the face of known non-compliance is itself a GCP violation.
How to document PI responsibilities correctly
The site initiation visit and training records
Before any participants can be enrolled, the PI and all site staff must complete ICH GCP training and protocol-specific training, and this training must be documented. The site initiation visit (SIV) is the formal point at which the sponsor confirms that the site is ready to begin the trial. The PI must be present at or directly engaged in the SIV, it is not appropriate to delegate attendance entirely to a coordinator.
Training records must be retained as essential documents for the duration of the study and the required post-study retention period. Under R3, training records must demonstrate not just that training occurred, but that the content was appropriate for the role and the specific trial.
Ongoing documentation obligations
Throughout the trial, the PI must ensure that source documents accurately reflect the trial conduct, that any deviations from the protocol are documented promptly with an explanation and corrective action, that serious adverse events are reported within the required timelines, and that the delegation log is kept current.
A practical approach used at well-run sites is a PI oversight log, a running record of the PI’s review activities, including monitoring visit responses, protocol deviation reviews, team meetings, and quality checks. While not formally required as a named document by GCP, this type of record demonstrates exactly the kind of proactive quality ownership that R3 expects of investigators.
Key takeaways
Principal investigator responsibilities form the backbone of ethical, compliant, and scientifically credible clinical research at site level. The PI cannot be a figurehead who signs documents and defers everything to the coordinator. Under ICH E6 R3, the PI is expected to be a genuine quality leader, engaged in feasibility assessment, active in oversight, proportionate in risk management, and personally accountable for everything that happens at the site.
The shift from R2 to R3 does not reduce the PI’s workload. It refocuses it. Less of the PI’s effort should go toward uniform process compliance and more toward identifying and protecting what matters most: participant safety and data integrity. This is a more demanding role intellectually, but also a more purposeful one.
For any physician or healthcare professional considering taking on the PI role for the first time, the message from R3 is clear: being qualified on paper is the starting point, not the finish line. Good Clinical Practice certification, protocol expertise, and a commitment to ongoing quality oversight are what the role genuinely requires.
Conclusion
The principal investigator is where GCP becomes real. Regulatory guidelines, sponsor requirements, and protocol procedures all converge at the site level, and the PI is the person who ensures they are implemented correctly, consistently, and with the participant’s wellbeing at the centre of every decision.
ICH E6 R3 has made principal investigator responsibilities GCP more explicit, more demanding, and more aligned with the complexity of modern clinical research. Investigators who trained under R2 and have not yet updated their understanding of the new framework are carrying a knowledge gap that will eventually surface, at a monitoring visit, at an inspection, or at the moment a participant’s safety depends on a decision being made correctly.
The good news is that R3, despite its additional demands, gives investigators something R2 did not fully offer: a framework that trusts their professional judgement. Proportionality means that a skilled, experienced PI running a well-managed site has more flexibility, not less. But that flexibility comes with accountability, and accountability begins with knowledge.
Is your ICH GCP training up to date with ICH E6 R3?
Principal investigator responsibilities under ICH GCP have changed significantly under the new guidelines. Whether you are a physician preparing to take on the PI role for the first time, a sub-investigator looking to advance, or an experienced investigator who trained under R2, our ICH GCP E6 R3 certification programme ensures you understand exactly what is required of you under the current standard.
If you are new to GCP and want to understand the full certification pathway first, start with our 2026 ICH GCP certification guide.
Our courses are accredited by the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK) and approved by TransCelerate, making your certificate recognised by sponsors and regulators worldwide.
Get your ICH GCP E6 R3 certification today.
Are you already certified under R2? Our R3 update course covers all the changes to investigator responsibilities, quality by design, proportionality, and decentralised trial oversight, everything you need to remain compliant and inspection-ready in 2026.
Are you ready to transition from clinical practice to research leadership?
Understanding the role of a principal investigator is critical, but setting up a site from scratch can be overwhelming. We’ve simplified the process for you.
Our “Setting Up a Successful Clinical Trial Site” course helps medical doctors enter clinical research with confidence. You will learn how to manage staff, navigate regulatory audits, and build a site that sponsors trust.
Sign up today and become a trial-ready principal investigator.
FAQ: Principal investigator responsibilities GCP
What are the main responsibilities of a principal investigator under GCP?
The principal investigator is responsible for the overall conduct of the clinical trial at the site. Core principal investigator responsibilities GCP include ensuring participant safety, overseeing the informed consent process, supervising all delegated team members, maintaining essential documents, ensuring protocol compliance, reporting adverse events, and communicating with the sponsor. Under ICH E6 R3, the PI is also responsible for contributing to quality by design and applying proportionate oversight throughout the trial.
What is the difference between a principal investigator and a sub-investigator?
The PI holds overall accountability for the site and cannot transfer that responsibility. A sub-investigator is a qualified team member to whom the PI has delegated specific trial tasks, documented on the delegation of authority log. Sub-investigators work under the PI’s supervision and within the scope of their delegation. The PI remains accountable for all activities at the site, including those performed by sub-investigators.
What is a delegation log in GCP and why is it important?
A delegation log is an essential document that records every trial-related task assigned to each team member at the site, along with their qualifications and the period during which the delegation is active. It must be signed by the PI and kept current throughout the trial. Under principal investigator responsibilities GCP, the PI must not only maintain this document but actively supervise the delegated activities it covers.
What are the new investigator responsibilities introduced in ICH E6 R3?
ICH E6 R3 introduces several new dimensions to principal investigator responsibilities GCP. These include active participation in identifying Critical to Quality factors, applying proportionate oversight based on trial risk, ensuring GCP compliance in decentralised and remote trial activities, maintaining ongoing competency rather than relying solely on historic training credentials, and contributing to quality management systems from the protocol feasibility stage.
Who can be a principal investigator in a clinical trial?
Under ICH GCP, a PI must be a qualified individual with the education, training, and experience necessary to assume responsibility for the proper conduct of the trial. In practice this is typically a licensed physician, though local regulations in some countries permit other qualified healthcare professionals to act as PI for certain types of studies. The PI must also have access to adequate resources, staff, facilities, and time, to conduct the trial properly.
What happens if a principal investigator does not comply with GCP?
Non-compliance with principal investigator responsibilities GCP can result in regulatory findings ranging from minor observations to critical violations. Serious non-compliance can lead to a clinical hold on the study, invalidation of site data, formal warning letters, and in severe cases the disqualification of the investigator from conducting future clinical trials. The sponsor also has obligations to act when PI non-compliance is identified.
Can a principal investigator delegate the informed consent process?
Yes, but with strict limitations. The PI may delegate the conduct of consent discussions to a qualified sub-investigator or CRC, provided this delegation is documented on the delegation log. However, the PI retains overall accountability for the quality and validity of the consent process at the site. Medical decisions arising from the consent process, including decisions about participant eligibility or safety, must involve a qualified physician.
How often should a principal investigator review trial data and documentation?
ICH E6 R3 does not specify a fixed frequency, but requires that the PI’s oversight be proportionate to the risks of the trial and ongoing throughout its conduct. Best practice is regular review of source documents, protocol deviation reports, adverse event assessments, and delegation log currency, the frequency depending on the complexity and risk profile of the study. A written record of these oversight activities is strongly advisable.
What is the PI's responsibility in a decentralised clinical trial?
Under R3, principal investigator responsibilities GCP extend fully to decentralised elements of a trial. Even when participants never attend the site, the PI remains accountable for the quality and compliance of all remote activities conducted under the study, including eConsent, remote assessments, wearable data collection, and home nurse visits. The PI must ensure these processes are properly documented, validated where required, and subject to appropriate oversight.
